Table 1.
Characteristics of included studies in meta-analysis
| Study, year/country [Reference] | Controls | Thyroid patients | Study characteristics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (M/F) | Mean age ± S.D. | Mean BMI ± S.D. | Thyroid type | N (M/F) | Mean age ± S.D. | Mean BMI ± S.D. | Disease duration | Thyroid treatment | IMA method, sample (units) | Matching | NOS | |
| Choudhury et al., 2015/India [37] | 43 | ? | ? | HT | 56 | ? | ? | ? | Not studied | Colorimetric, serum (ABU) | Age and sex | 5 |
| Dahiya et al., 2014/India [15] | 50 (5/45) | 38.1 ± 11.8 | 22.3 ± 1.9 | HT | 50 (4/46) | 37.9 ± 13.6 | 32.4 ± 2.1 | Newly diagnosed | Not studied | Colorimetric, serum (ABU) | Age and sex | 6 |
| Erem et al., 2016/Turkey [38] | 30 (9/21) | 51.6 ± 17.04 | 26.53 ± 3.2 | HT | 30 (6/24) | 46.3 ± 14.34 | 26.33 ± 3.16 | 3.17 | Studied | Colorimetric, serum (ABU) | Age, sex, BMI and BP | 8 |
| SHT | 25 (8/17) | 47.72 ± 13.6 | 27.08 ± 3.27 | 2.92 | ||||||||
| Erem et al., 2015/Turkey [16] | 30 (9/12) | 51.6 ± 17.0 | 26.5 ± 3.2 | HYT | 45 (12/33) | 50.5 ± 18.0 | 25.0 ± 3.5 | 2.4 years | Studied | Colorimetric, serum (ABU) | Age and BMI | 8 |
| SHYT | 20 (3/17) | 56.1 ± 19.3 | 26.6 ± 3.6 | 2.5 years | ||||||||
| Ersoy et al., 2013/Turkey [17] | 48 (5/43) | 40.0 ± 12.2 | 30.2 ± 6.6 | HT | 13 (4/9) | 43.2 ± 12.4 | 29.7 ± 6.5 | ? | Not studied | Colorimetric, serum (ABU) | Age, BMI, waist circumference and BP | 7 |
| SHT | 24 (2/22) | 38.0 ± 11.6 | 28.8 ± 5.7 | ? | ||||||||
| Lakshminarayana et al., 2014/India [18] | 50 (23/27) | ? | ? | SHT | 50 | No/Unclear | No/Unclear | ? | Not studied | Colorimetric, serum (ABU) | Age and sex matched | 4 |
| Ma et al., 2012/China [19] | 35 (15/20) | 43.0 ± 12.0 | 24.2 ± 0.9 | HT | 35 (10/25) | 43.0 ± 11.0 | 25.9 ± 1.4 | 36 ± 10 months | Studied | Commercial kit, serum (U/ml) | Age, sex and SBP | 7 |
| HYT | 35 (13/22) | 40 ± 13 | 23.8 ± 1.1 | 24 ± 2 months | ||||||||
| Oncel et al., 2014/Turkey [20] | 27 (3/24) | 38 ± 15.3 | No/Unclear | HT | 34 (2/32) | 37 ± 14.7 | No/unclear | Newly diagnosed | Not studied | Colorimetric, serum (ABU) | Age and sex | 5 |
| HYT | 27 (4/23) | 45 ± 15.7 | No/unclear | |||||||||
| Rangaswamy et al., 2014/India [21] | 30 | ? | ? | HYT | 30 | No/Unclear | No/unclear | Newly diagnosed | Not studied | Colorimetric, serum (ABU) | Age and sex | 4 |
| Reddy et al., 2015/India [23] | 35 (10/25) | 33.5 ± 6.8 | 20.1 ± 1.2 | HT | 35 (10/25) | 33.7 ± 9.7 | 24.7 ± 3.0 | Newly diagnosed | Not studied | Colorimetric, serum (ABU) | Age and BP | 7 |
| SHT | 35 (2/33) | 33.8 ± 9.4 | 23.7 ± 3.8 | |||||||||
| Roy et al., 2015/India [28] | 40 | 20–45 | ? | HT and SHT | 30 | 20–45 | ? | ? | Not studied | Colorimetric, serum (IMA Units) | Age and sex | 5 |
| Verma et al., 2013/India [22] | 50 (4/46) | 38.1 ± 11.8 | 31.2 ± 0.8 | HYT | 50 (6/44) | 44.4 ± 14.4 | 27.3 ± 0.7 | Newly diagnosed | Not studied | Colorimetric, serum (ABU) | Age and sex | 6 |
N, total sample size; M: male; F: female; TT3: total tri-iodothyronine; TT4: total tetra-iodothyronine; TgAb: thyroglobulin antibodies; TPOAb: thyroperoxidase antibodies; FT3: free tri-iodothyronine; FT4: free tetra-iodothyronine; BP: blood pressure; SBP: systolic blood pressure; ?: not available/unclear.